DOCSLIB.ORG

Disclaimer: Price Listing Does Not Guarantee Coverage

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disclaimer: Price Listing Does Not Guarantee Coverage West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 2/24/2017 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date 0.9 % SODIUM CHLORIDE INJECTION VIAL (ML) 0.9 % 0.05712 08/12/2014 0.9 % SODIUM CHLORIDE INTRAVENOUS INTRAVENOUS SOLUTION 0.9 0.00196 03/06/2015 0.00196 08/21/2015 % 0.9 % SODIUM CHLORIDE INTRAVENOUS PIGGYBACK WITH THREADED 0.03505 01/30/2015 0.03505 08/21/2015 PORT (ML) 0.9 % SODIUM CHLORIDE INTRAVENOUS PIGGYBACK WITH VIAL PORT 0.04175 07/18/2014 (NON-THREADED) ABACAVIR SULFATE ORAL TABLET 300 MG 5.57996 04/24/2015 3.25000 11/20/2015 ACAMPROSATE CALCIUM ORAL TABLET, DELAYED RELEASE (ENTERIC 0.81000 01/27/2017 COATED) 333 MG ACARBOSE ORAL TABLET 100 MG 0.32897 08/21/2015 0.27550 09/30/2016 ACARBOSE ORAL TABLET 25 MG 0.23329 10/10/2014 0.23329 08/21/2015 ACARBOSE ORAL TABLET 50 MG 0.25460 08/21/2015 0.17333 05/20/2016 ACEBUTOLOL HCL ORAL CAPSULE 200 MG 0.21197 02/13/2015 0.21197 08/21/2015 ACEBUTOLOL HCL ORAL CAPSULE 400 MG 0.26000 03/27/2015 0.26000 08/21/2015 ACETAMINOPHEN ORAL CAPSULE 500 MG 0.01093 08/12/2014 ACETAMINOPHEN ORAL DROPS 80MG/0.8ML 0.17160 10/11/2013 0.17160 08/21/2015 ACETAMINOPHEN ORAL ELIXIR 160 MG/5ML 0.01083 09/27/2013 ACETAMINOPHEN ORAL LIQUID (ML) 160 MG/5ML 0.00932 09/27/2013 0.00932 08/21/2015 ACETAMINOPHEN ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 160 0.02137 08/21/2015 0.02033 02/17/2017 MG/5ML ACETAMINOPHEN ORAL TABLET 325 MG 0.00830 06/20/2014 0.00830 08/21/2015 ACETAMINOPHEN ORAL TABLET 500 MG 0.01040 04/03/2015 0.01040 08/21/2015 ACETAMINOPHEN ORAL TABLET, CHEWABLE 80 MG 0.04651 04/03/2015 0.04651 08/21/2015 ACETAMINOPHEN ORAL TABLET,DISINTEGRATING 80 MG 0.05113 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 120 MG 0.20324 08/22/2014 0.20324 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 325 MG 0.46400 08/22/2014 0.46400 08/21/2015 ACETAMINOPHEN RECTAL SUPPOSITORY, RECTAL 650 MG 0.21762 08/22/2014 0.21762 08/21/2015 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.01332 01/30/2015 0.01332 08/21/2015 120-12MG/5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.21394 03/27/2015 0.21394 08/21/2015 120-12MG/5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL SOLUTION, ORAL 0.10079 03/27/2015 0.10079 08/21/2015 300MG/12.5 ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.14344 09/19/2014 0.14344 08/21/2015 15MG ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.12060 05/01/2015 0.12060 08/21/2015 30MG ACETAMINOPHEN WITH CODEINE PHOSPHATE ORAL TABLET 300MG- 0.22780 08/21/2015 0.19101 05/20/2016 60MG ACETAMINOPHEN/DIPHENHYDRAMINE HCL ORAL TABLET 500MG-25MG 0.04047 04/24/2015 0.04047 08/21/2015 ACETAZOLAMIDE ORAL CAPSULE, EXTENDED RELEASE 500 MG 2.53225 11/20/2015 2.01798 03/25/2016 ACETAZOLAMIDE ORAL TABLET 125 MG 1.52593 01/24/2014 1.52593 08/21/2015 ACETAZOLAMIDE ORAL TABLET 250 MG 2.01817 11/28/2014 ACETIC ACID IRRIGATION SOLUTION, IRRIGATION 0.25 % 0.00350 03/01/2013 ACETIC ACID OTIC SOLUTION, NON-ORAL 2 % 1.81591 06/28/2013 1.81591 08/21/2015 ACETIC ACID/ALUMINUM ACETATE OTIC DROPS 2 % 0.84000 01/25/2013 0.84000 08/21/2015 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 2/24/2017 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date ACETIC ACID/HYDROCORTISONE OTIC DROPS 2 %-1 % 9.82215 08/21/2015 8.85454 01/13/2017 ACETYLCYSTEINE INTRAVENOUS VIAL (ML) 200 MG/ML 5.26400 03/06/2015 5.26400 08/21/2015 ACETYLCYSTEINE MISCELLANEOUS VIAL (ML) 100 MG/ML 0.45068 08/12/2014 0.45068 08/21/2015 ACETYLCYSTEINE MISCELLANEOUS VIAL (ML) 200 MG/ML 0.39190 02/13/2015 0.39190 08/21/2015 ACETYLCYSTEINE/MECOBALAMIN/LEVOMEFOLATE CALCIUM ORAL 1.89794 02/20/2015 1.89794 08/21/2015 TABLET 600-2-6 MG ACITRETIN ORAL CAPSULE 10 MG 17.18010 11/14/2014 ACITRETIN ORAL CAPSULE 17.5 MG 42.31920 03/21/2014 ACITRETIN ORAL CAPSULE 25 MG 25.13519 09/12/2014 23.09605 09/30/2016 ACYCLOVIR ORAL CAPSULE 200 MG 0.08844 03/27/2015 0.08844 08/21/2015 ACYCLOVIR ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 200 MG/5ML 0.65886 09/19/2014 0.65886 08/21/2015 ACYCLOVIR ORAL TABLET 400 MG 0.10104 04/10/2015 0.10104 08/21/2015 ACYCLOVIR ORAL TABLET 800 MG 0.18452 03/27/2015 0.18452 08/21/2015 ACYCLOVIR SODIUM INTRAVENOUS VIAL (EA) 500 MG 31.20600 08/22/2014 31.20600 08/21/2015 ACYCLOVIR SODIUM INTRAVENOUS VIAL (ML) 50 MG/ML 1.40750 07/25/2014 ACYCLOVIR TOPICAL OINTMENT (GRAM) 5 % 18.88402 08/21/2015 17.89067 07/08/2016 ADAPALENE TOPICAL CREAM (GRAM) 0.1 % 3.51289 04/26/2013 ADAPALENE TOPICAL GEL (GRAM) 0.1 % 3.05760 01/25/2013 2.60534 07/08/2016 ADAPALENE TOPICAL GEL (GRAM) 0.3 % 4.68580 11/07/2014 4.68580 08/21/2015 ADAPALENE TOPICAL GEL WITH PUMP (GRAM) 0.3 % 4.61985 04/10/2015 4.61985 08/21/2015 ADEFOVIR DIPIVOXIL ORAL TABLET 10 MG 26.52627 09/27/2013 ALBUMIN HUMAN INTRAVENOUS INTRAVENOUS SOLUTION 25 % 1.51200 05/01/2015 1.51200 08/21/2015 ALBUMIN HUMAN INTRAVENOUS INTRAVENOUS SOLUTION 5 % 0.21588 09/19/2014 0.21588 08/21/2015 ALBUTEROL SULFATE INHALATION SOLUTION, NON-ORAL 5 MG/ML 0.72066 10/18/2013 0.72066 08/21/2015 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (EA) 2.5 MG/0.5 0.43876 08/01/2014 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 0.63MG/3ML 0.35633 12/05/2014 0.35633 08/21/2015 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 1.25MG/3ML 0.37645 08/21/2015 0.28465 05/20/2016 ALBUTEROL SULFATE INHALATION VIAL, NEBULIZER (ML) 2.5 MG/3ML 0.05253 04/03/2015 0.05253 08/21/2015 ALBUTEROL SULFATE ORAL SYRUP 2 MG/5 ML 0.01277 05/24/2013 0.01277 08/21/2015 ALBUTEROL SULFATE ORAL TABLET 2 MG 4.56651 08/21/2015 4.05000 12/25/2015 ALBUTEROL SULFATE ORAL TABLET 4 MG 4.11250 08/21/2015 3.62765 12/25/2015 ALBUTEROL SULFATE ORAL TABLET, EXTENDED RELEASE 12 HR 4 MG 1.18451 04/25/2014 ALBUTEROL SULFATE ORAL TABLET, EXTENDED RELEASE 12 HR 8 MG 1.71821 04/05/2013 ALCLOMETASONE DIPROPIONATE TOPICAL CREAM (GRAM) 0.05 % 1.30908 06/21/2013 ALCLOMETASONE DIPROPIONATE TOPICAL OINTMENT (GRAM) 0.05 % 0.58692 06/28/2013 ALENDRONATE SODIUM ORAL SOLUTION, ORAL 70 MG/75ML 2.45700 09/27/2013 ALENDRONATE SODIUM ORAL TABLET 10 MG 0.18750 08/12/2014 0.18750 08/21/2015 ALENDRONATE SODIUM ORAL TABLET 35 MG 0.52484 11/07/2014 0.52484 08/21/2015 ALENDRONATE SODIUM ORAL TABLET 40 MG 2.80060 03/27/2015 ALENDRONATE SODIUM ORAL TABLET 5 MG 0.18110 08/12/2014 0.18110 08/21/2015 ALENDRONATE SODIUM ORAL TABLET 70 MG 0.52484 08/21/2015 0.46500 12/02/2016 ALFUZOSIN HCL ORAL TABLET, EXTENDED RELEASE 24 HR 10 MG 0.13697 04/17/2015 0.13697 08/21/2015 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 2/24/2017 Disclaimer: Price listing does not guarantee coverage Generic Name Prev. SMAC Price Prev. Effective Current SMAC Current Effective Date Price Date ALLOPURINOL ORAL TABLET 100 MG 0.16332 11/28/2014 0.16332 08/21/2015 ALLOPURINOL ORAL TABLET 300 MG 0.43385 03/25/2016 0.33844 05/20/2016 ALPHA LIPOIC ACID ORAL CAPSULE 200 MG 0.12771 08/08/2014 0.12771 08/21/2015 ALPHA LIPOIC ACID ORAL CAPSULE 50 MG 0.10210 08/12/2014 0.10210 08/21/2015 ALPRAZOLAM ORAL TABLET 0.25 MG 0.01509 05/16/2014 0.01509 08/21/2015 ALPRAZOLAM ORAL TABLET 0.5 MG 0.01780 04/17/2015 0.01780 08/21/2015 ALPRAZOLAM ORAL TABLET 1 MG 0.01970 02/06/2015 0.01970 08/21/2015 ALPRAZOLAM ORAL TABLET 2 MG 0.04007 08/21/2015 0.07213 09/28/2015 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 0.5 MG 0.36136 08/12/2014 0.36136 08/21/2015 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 1 MG 0.44913 08/12/2014 0.44913 08/21/2015 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 2 MG 0.41600 08/12/2014 0.41600 08/21/2015 ALPRAZOLAM ORAL TABLET, EXTENDED RELEASE 24 HR 3 MG 0.79340 08/21/2015 0.55483 11/20/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 0.25 MG 1.36123 03/01/2013 1.36123 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 0.5 MG 1.51669 01/25/2013 1.51669 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 1 MG 2.02358 01/25/2013 2.02358 08/21/2015 ALPRAZOLAM ORAL TABLET,DISINTEGRATING 2 MG 3.00202 01/25/2013 3.00202 08/21/2015 ALUMINUM HYDROXIDE ORAL SUSPENSION, ORAL (FINAL DOSE FORM) 0.00813 08/21/2015 320 MG/5ML AMANTADINE HCL ORAL CAPSULE 100 MG 1.15992 04/22/2016 1.10704 08/26/2016 AMANTADINE HCL ORAL SOLUTION, ORAL 50 MG/5 ML 0.01733 04/03/2015 0.01733 08/21/2015 AMANTADINE HCL ORAL TABLET 100 MG 1.59829 04/12/2013 AMCINONIDE TOPICAL CREAM (GRAM) 0.1 % 2.82140 08/12/2014 AMCINONIDE TOPICAL LOTION (ML) 0.1 % 1.90000 08/12/2014 AMCINONIDE TOPICAL OINTMENT (GRAM) 0.1 % 4.53600 08/30/2013 AMIKACIN SULFATE INJECTION VIAL (ML) 1000MG/4ML 3.14373 12/05/2014 3.14373 08/21/2015 AMIKACIN SULFATE INJECTION VIAL (ML) 500 MG/2ML 2.95555 12/05/2014 2.95555 08/21/2015 AMILORIDE HCL ORAL TABLET 5 MG 0.49564 02/13/2015 0.49564 08/21/2015 AMILORIDE HCL/HYDROCHLOROTHIAZIDE ORAL TABLET 5 MG-50 MG 0.42250 05/30/2014 0.42250 08/21/2015 AMINO ACIDS ORAL POWDER (GRAM) 0.25540 08/12/2014 AMINOCAPROIC ACID INTRAVENOUS VIAL (ML) 250 MG/ML 0.08148 02/06/2015 0.08148 08/21/2015 AMINOCAPROIC ACID ORAL TABLET 1000 MG 18.30610 08/12/2014 18.30610 08/21/2015 AMINOCAPROIC ACID ORAL TABLET 500 MG 5.37896 10/11/2013 5.37896 08/21/2015 AMINOPHYLLINE INTRAVENOUS VIAL (ML) 250MG/10ML 0.30912 01/30/2015 0.30912 08/21/2015 AMINOPHYLLINE INTRAVENOUS VIAL (ML) 500MG/20ML 0.07270 08/12/2014 AMIODARONE HCL INTRAVENOUS AMPUL (ML) 50 MG/ML 0.33600 01/25/2013 AMIODARONE HCL ORAL TABLET 100 MG 2.55717 03/21/2014 AMIODARONE HCL ORAL TABLET 200 MG 0.16103 08/21/2015 0.12724 09/30/2016 AMIODARONE HCL ORAL TABLET 400 MG 3.19526 08/22/2014 2.81936 12/02/2016 AMITRIPTYLINE HCL ORAL TABLET 10 MG 0.15732 04/03/2015 0.15732 08/21/2015 AMITRIPTYLINE HCL ORAL TABLET 100 MG 1.00016 08/21/2015 0.86682 09/30/2016 AMITRIPTYLINE HCL ORAL TABLET 150 MG 1.40116 08/21/2015 1.71450 10/01/2015 AMITRIPTYLINE HCL ORAL TABLET 25 MG 0.26664 04/03/2015 0.26664 08/21/2015 West Virginia Medicaid State Maximum Allowable Cost (SMAC) List Effective 2/24/2017 Disclaimer: Price listing does not guarantee coverage Generic Name Prev.
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Comparison of the Anti-Inflammatory Effects of Cilomilast, Budesonide
    Ratcliffe and Dougall BMC Pharmacology and Toxicology 2012, 13:15 http://www.biomedcentral.com/2050-6511/13/15 RESEARCH ARTICLE Open Access Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages Marianne Jennifer Ratcliffe1* and Iain Gordon Dougall2 Abstract Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by a largely irreversible airflow obstruction and a persistent, excessive inflammatory response. Alveolar macrophages (AMs) are increased in the lungs of COPD patients, and act as orchestrators of the inflammatory response, releasing a range of mediators to coordinate recruitment and activation of leukocytes. Attempts to treat the inflammatory component of COPD with anti-inflammatory drugs such as steroids has met with limited success. In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. All studies were carried out with appropriate ethical approval and written, informed consent was obtained from each subject. Cilomilast had little effect on cytokine release from AMs. There was considerable variability in the responsiveness of AMs to Budesonide, with a subset of AMs responding poorly to Budesonide. BIRB-796 inhibited TNFα release from all AM donors, including those that responded poorly to steroids. Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release. These results suggest that a p38 inhibitor may provide advantages over existing anti-inflammatory treatments for COPD, either as an add-on to existing therapy, or to treat patients who respond poorly to steroids.
    [Show full text]
  • Guanidine-Containing Polyhydroxyl Macrolides: Chemistry, Biology, and Structure-Activity Relationship
    molecules Review Guanidine-Containing Polyhydroxyl Macrolides: Chemistry, Biology, and Structure-Activity Relationship Xiaoyuan Song 1, Ganjun Yuan 1,* , Peibo Li 2 and Sheng Cao 1 1 College of Bioscience and Bioengineering, Jiangxi Agricultural University, Nanchang 330045, China; [email protected] (X.S.); [email protected] (S.C.) 2 School of Life Sciences, Sun Yat-sen University, 135 Xingang Road, Guangzhou 510275, China; [email protected] * Correspondence: [email protected]; Tel.: +86-0791-83813459 Academic Editor: Jesus Simal-Gandara Received: 7 October 2019; Accepted: 29 October 2019; Published: 30 October 2019 Abstract: Antimicrobial resistance has been seriously threatening human health, and discovering new antimicrobial agents from the natural resource is still an important pathway among various strategies to prevent resistance. Guanidine-containing polyhydroxyl macrolides, containing a polyhydroxyl lactone ring and a guanidyl side chain, can be produced by many actinomycetes and have been proved to possess many bioactivities, especially broad-spectrum antibacterial and antifungal activities. To explore the potential of these compounds to be developed into new antimicrobial agents, a review on their structural diversities, spectroscopic characterizations, bioactivities, acute toxicities, antimicrobial mechanisms, and the structure-activity relationship was first performed based on the summaries and analyses of related publications from 1959 to 2019. A total of 63 guanidine-containing polyhydroxyl macrolides were reported, including
    [Show full text]
  • Mediated Pulmonary Hypertension in Neonatal Rats: a Role for Products of Lipid Peroxidation
    0031-3998/00/4803-0289 PEDIATRIC RESEARCH Vol. 48, No. 3, 2000 Copyright © 2000 International Pediatric Research Foundation, Inc. Printed in U.S.A. Endothelin-1 and O2-Mediated Pulmonary Hypertension in Neonatal Rats: A Role for Products of Lipid Peroxidation ROBERT P. JANKOV, XIAOPING LUO, JUDY CABACUNGAN, ROSETTA BELCASTRO, HELENA FRNDOVA, STEPHEN J. LYE, AND A. KEITH TANSWELL Medical Research Council Group in Lung Development and Lung Biology Programme [R.P.J., X.L., J.C., R.B., H.F., A.K.T.], Hospital for Sick Children Research Institute, the MRC Group in Developmental and Fetal Health, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital [S.J.L.], and the Departments of Obstetrics and Gynaecology [S.J.L.], Paediatrics [A.K.T.] and Physiology [A.K.T., S.J.L.], University of Toronto, Toronto, Ontario, M5S 1A8 Canada. ABSTRACT We hypothesized that reactive O2 species, or their interme- lung cell cultures. We conclude that reactive O2 species, or their diary products, generated during exposure to elevated O2 lead to bioactive intermediaries, are causative in O2-mediated pulmo- pathologic endothelin-1 expression in the newborn lung. Endo- nary hypertension and endothelin-1 up-regulation. It is likely that thelin-1 expression and 8-isoprostane content (an in vivo marker the bioactive lipid peroxidation product, 8-isoprostane, plays a of lipid peroxidation) were examined and found to be elevated key role in pathologic endothelin-1 expression and pulmonary (p Ͻ 0.05) in the lungs of newborn rats with abnormal lung hypertension during oxidant stress. (Pediatr Res 48: 289–298, morphology and pulmonary hypertension, as assessed by right 2000) ventricular hypertrophy, after a 14-d exposure to 60% O2.
    [Show full text]
  • Basic Concepts in Medicinal Chemistry, 2Nd Edition
    APP ANSWERS TO CHAPTER QUESTIONS CHAPTER 2 STRUCTURE ANALYSIS CHECKPOINT Checkpoint Drug 1: Venetoclax 1. Answers provided in table below. Functional Group Name Contribution to Water and/or Lipid Solubility A Halogen (chlorine atom) Lipid Solubility B Alicyclic ring, alkyl ring, cycloalkane Lipid Solubility C Tertiary amine (piperazine) Water Solubility D Heterocyclic ring system (pyrrolopyridine) Hydrocarbons: Lipid Solubility Nitrogen atoms: Water Solubility E Aromatic ring; phenyl ring; aromatic hydrocarbon Lipid Solubility F Sulfonamide Water Solubility G Secondary aromatic amine/aniline Water Solubility H Ether Hydrocarbons: Lipid Solubility Oxygen atom: Water Solubility 2. The sulfonamide and tertiary amine will be primarily ionized in most physiological environments and can participate in ion-dipole interactions (as the ion) with water. In the event that they are unionized, they could participate in hydrogen bonding interactions with water. The nitrogen atoms of the heterocyclic ring system, as well as the secondary aromatic amine, and the oxygen atom of the ether will not be appreciably ionized, but can participate in hydrogen bonding interactions with water. Thus, all of these functional groups contribute to the water solubility of venetoclax. The halogen as well as the hydrocarbon chains and rings are not able to ionize or form hydrogen bonds with water and thus contribute to the lipid solubility of venetoclax. 477 Unauthenticated | Downloaded 09/26/21 09:50 PM UTC 478 BASIC CONCEPTS IN MEDICINAL CHEMISTRY 3. Answers provided in table below. Electron Donating or Withdrawing Resonance or Induction A Electron Withdrawing Induction B Both Donates electrons into the aromatic ring through resonance. Withdraws electrons from adjacent methylene groups through induction.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Guadinomines, Type III Secretion System Inhibitors, Produced by Streptomyces Sp
    J. Antibiot. 61(4): 222–229, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Guadinomines, Type III Secretion System Inhibitors, Produced by Streptomyces sp. K01-0509 I. Taxonomy, Fermentation, Isolation and Biological Properties Masato Iwatsuki, Ryuji Uchida, Hitomi Yoshijima, Hideaki Ui, Kazuro Shiomi, Atsuko Matsumoto, Yoko Takahashi, Akio Abe, Hiroshi Tomoda, Satoshi O¯ mura Dedicated to the late Prof. Shigeo Iwasaki Received: January 22, 2008 / Accepted: April 4, 2008 © Japan Antibiotics Research Association Abstract Enteropathogenic Escherichia coli (EPEC) Chlamydia spp. [4]. These bacteria use TTSS to deliver expressing the Type III secretion system (TTSS) induced effector proteins into the cytosol of the eukaryotic target hemolysis of sheep blood cells. Using this assay, six cell and depend on their respective TTSS to invade the structurally related compounds designated as guadinomines host, resist phagocytosis, grow in deep tissues, and cause were isolated as inhibitors of TTSS-induced hemolysis by disease [5]. Recent studies have revealed that TTSS is not ion exchange column chromatography and HPLC from the essential for the survival of bacteria and is not found in culture broth of Streptomyces sp. K01-0509. Guadinomines non-pathogenic Gram-negative bacteria except for some A and B showed potent inhibition with IC50 values of 0.02 kinds of symbiotic bacteria. and 0.007 mg/ml, respectively, guadinomine D showed Based on the new concept of “anti-infective drugs” ¯ moderate activity (IC50: 8.5 mg/ml), while guadinomines C1 developed by Omura [6], we have focused on TTSS as a and C2 and guadinomic acid had no activity. new target for anti-infective drugs.
    [Show full text]
  • Bioisosteric Replacement As a Tool in Anti-HIV Drug Design
    pharmaceuticals Review Bioisosteric Replacement as a Tool in Anti-HIV Drug Design Alexej Dick and Simon Cocklin * Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Rooms 10307, 10309, and 10315, 245 North 15th Street, Philadelphia, PA 19102, USA; [email protected] * Correspondence: [email protected]; Tel.: +215-762-7234 or +215-762-4979 Received: 3 February 2020; Accepted: 26 February 2020; Published: 28 February 2020 Abstract: Bioisosteric replacement is a powerful tool for modulating the drug-like properties, toxicity, and chemical space of experimental therapeutics. In this review, we focus on selected cases where bioisosteric replacement and scaffold hopping have been used in the development of new anti-HIV-1 therapeutics. Moreover, we cover field-based, computational methodologies for bioisosteric replacement, using studies from our group as an example. It is our hope that this review will serve to highlight the utility and potential of bioisosteric replacement in the continuing search for new and improved anti-HIV drugs. Keywords: bioisosteres; HIV-1; antiviral; computer-aided drug design; envelope; reverse transcriptase; protease; integrase; tat; Vif 1. Introduction The design and development of a lead compound into a drug is a laborious and often costly process, with most candidates failing due to metabolism and pharmacokinetics issues rather than potency. Bioisosteric replacement is a strategy used by medicinal chemists to address these limitations while still retaining the potency/efficacy of the initial lead compound. The use of bioisosteres and the introduction of structural changes to the lead compound allows the chemist to alter the compound’s size, shape, electronic distribution, polarizability, dipole, polarity, lipophilicity, and pKa, while still retaining potent target engagement.
    [Show full text]
  • 1 Identification of a Small Molecule Inhibitor of the Aminoglycoside 6'-N
    bioRxiv preprint doi: https://doi.org/10.1101/198176; this version posted October 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Identification of a Small Molecule Inhibitor of the Aminoglycoside 6'-N- 2 Acetyltransferase Type Ib [AAC(6')-Ib] Using Mixture-Based Combinatorial 3 Libraries 4 5 Tung Tran,1* Kevin Chiem,1* Saumya Jani,1 Brock A. Arivett, 2,3 David Lin,1 Rupali 6 Lad,1 Verónica Jimenez,1 Mary B. Farone, 2 Ginamarie Debevec,4 Radleigh 7 Santos,4 Marc Giulianotti,4 Clemencia Pinilla,5 and Marcelo E. Tolmasky1# 8 9 1Center for Applied Biotechnology Studies, Department of Biological Science, 10 College of Natural Sciences and Mathematics, California State University 11 Fullerton, Fullerton, CA, Departments of 2Biology and 3Chemistry, Middle 12 Tennessee State University, Murfreesboro, TN, 4Torrey Pines Institute for 13 Molecular Studies, Port St. Lucie, FL, and 5Torrey Pines Institute for Molecular 14 Studies, San Diego, CA. 15 16 Word count: 3,879 17 Running Head: Inhibition of AAC(6’)-Ib 18 19 Corresponding Author: Marcelo E. Tolmasky, Professor 20 Mailing address: Department of Biological Science, CNSM, CSUF, PO Box 6850, 21 Fullerton, CA 92831-6850, US. Email: [email protected] 22 23 Co-corresponding Author: Clemencia Pinilla 24 Mailing address: 3550 General Atomics Court, 2-129, San Diego CA 92121-1122, US. 25 Email: [email protected], for or questions related to combinatorial libraries 26 27 *Tung Tran and Kevin Chiem contributed equally to this article 1 bioRxiv preprint doi: https://doi.org/10.1101/198176; this version posted October 4, 2017.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0263257 A1 Elmaleh Et Al
    US 20160263257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0263257 A1 Elmaleh et al. (43) Pub. Date: Sep. 15, 2016 (54) CROMOLYN DERVATIVES AND RELATED (52) U.S. Cl. METHODS OF IMAGING AND TREATMENT CPC ......... A61K 51/0421 (2013.01); A61K 9/4808 (2013.01); A61K 9/0075 (2013.01); A61 K (71) Applicants: David R. ELMALEH, Newton, MA 9/0053 (2013.01); A61K 31/192 (2013.01); (US); Timothy SHOUP, Waltham, MA A61K 31/352 (2013.01); A61K 9/0019 (US) (2013.01) (57) ABSTRACT (72) Inventors: David R. Elmaleh, Newton, MA (US); Novel cromolyn analogs useful as imaging agents for detect Timothy M. Shoup, Waltham, MA ing atherosclerotic plaques and for treating atherosclerosis (US) and Alzheimer's Disease, and methods of making the cro molyn analogs, are disclosed. The cromolyn analogs have (21) Appl. No.: 15/031,098 the general formula: (22) PCT Fed: Oct. 22, 2014 (I) (86) PCT No.: PCT/US1.4f61694 O S 371 (c)(1), (2) Date: Apr. 21, 2016 Related U.S. Application Data (II) (63) Continuation of application No. 14/059.924, filed on Oct. 22, 2013. Publication Classification COH: (51) Int. C. A6 IK 5L/04 (2006.01) wherein X is OH, C-C alkoxyl: Y and Z are independently A6 IK3I/352 (2006.01) selected from a C-C alkyl, C-C alkoxyl, halogen, mi A6 IK3I/92 (2006.01) substituted or C-C substituted amine, F, F, or H; and n A6 IK 9/48 (2006.01) is 1, 2, or 3; and wherein for structure (I), if n are both 1 and A6 IK 9/00 (2006.01) Y and Z are both H and X is OH.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]